Inovio Pharmaceuticals Inc. (Nasdaq: INO) narrowed fourth quarter losses more than expected to 12 cents per share from 30 cents per share in the year ago period and announced that it received a five year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development Program grant. The stock price soared $1.43 to $8.47.